Loading...
TNG logo

Transgene SAENXTPA:TNG Stock Report

Market Cap €225.6m
Share Price
€0.82
n/a
1Y19.2%
7D-9.1%
Portfolio Value
​
View

Transgene SA

ENXTPA:TNG Stock Report

Market Cap: €225.6m

Transgene (TNG) Stock Overview

A biotechnology company, designs and develops therapeutic vaccines and oncolytic viruses for the treatment of cancer in France. More details

TNG fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance0/6
Financial Health2/6
Dividends0/6

Rewards

Revenue is forecast to grow 34.83% per year

Risk Analysis

Negative shareholders equity

Shareholders have been substantially diluted in the past year

Volatile share price over the past 3 months compared to the French market

Currently unprofitable and not forecast to become profitable over the next 3 years


TNG Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

TNG logo
Transgene

TG4050 Trial And Pipeline Developments Will Transform Cancer Vaccines

Key Takeaways Progress in TG4050 trials could establish Transgene as a leader in cancer vaccines, boosting reputation and revenue opportunities. Enhanced manufacturing capabilities are expected to improve net margins by reducing costs and increasing efficiency.
View narrative
€2
FV
58.8% undervalued intrinsic discount
58.23%
Revenue growth p.a.
16
users have viewed this narrative
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
TNG logo
Transgene

Accelerated Aging And Healthcare Reforms Will Spark Immunotherapy Breakthroughs

Key Takeaways Accelerated trial success and regulatory pathways could lead to earlier revenue, with large pharma partnerships boosting near-term financial stability. Expanding pipeline and partnerships, driven by aging demographics and innovative technology, position Transgene for transformative, recurring revenue growth and higher margins.
View narrative
€2.6
FV
68.3% undervalued intrinsic discount
102.29%
Revenue growth p.a.
5
users have viewed this narrative
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
TNG logo
Transgene

High-Risk Clinical Trials And Rising Costs Will Delay Returns Yet Unlock Value

Key Takeaways Reliance on early-stage pipeline, extended clinical timelines, and delayed revenue risk are compounded by heavy R&D spending and ongoing losses without approved products. Competitive pressures, regulatory challenges, and dependence on external partnerships create uncertainty around commercialization prospects, long-term profitability, and future funding stability.
View narrative
€1.1
FV
25.1% undervalued intrinsic discount
33.03%
Revenue growth p.a.
2
users have viewed this narrative
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
View Stock Community
UNCY logo
Unicycive Therapeutics

Looking to be second time lucky with a game-changing new product

Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more

View narrative
1.1k
users have viewed this narrative
4users have liked this narrative
0users have commented on this narrative
21users have followed this narrative
US$21.53
68.9% undervalued intrinsic discount
stuart_roberts's Fair Value
Profit Margin
20%
Future PE
27x
Price in 2030
US$34.67

Transgene SA Competitors

Price History & Performance

Summary of share price highs, lows and changes for Transgene
Historical stock prices
Current Share Price€0.82
52 Week High€1.50
52 Week Low€0.53
Beta0.67
1 Month Change-12.90%
3 Month Change-30.46%
1 Year Change19.25%
3 Year Change-61.04%
5 Year Change-67.04%
Change since IPO-98.17%

Recent News & Updates

Recent updates

Is Transgene (EPA:TNG) Using Too Much Debt?

May 27
Is Transgene (EPA:TNG) Using Too Much Debt?
User avatar

TG4050 Trial And Pipeline Developments Will Transform Cancer Vaccines

Progress in TG4050 trials could establish Transgene as a leader in cancer vaccines, boosting reputation and revenue opportunities.

Is Transgene (EPA:TNG) Using Too Much Debt?

Jun 15
Is Transgene (EPA:TNG) Using Too Much Debt?

Downgrade: Here's How Analysts See Transgene SA (EPA:TNG) Performing In The Near Term

Mar 21
Downgrade: Here's How Analysts See Transgene SA (EPA:TNG) Performing In The Near Term

Transgene SA (EPA:TNG) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Mar 19
Transgene SA (EPA:TNG) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Does Transgene (EPA:TNG) Have A Healthy Balance Sheet?

Mar 18
Does Transgene (EPA:TNG) Have A Healthy Balance Sheet?

Transgene (EPA:TNG) Has Debt But No Earnings; Should You Worry?

Nov 24
Transgene (EPA:TNG) Has Debt But No Earnings; Should You Worry?

Health Check: How Prudently Does Transgene (EPA:TNG) Use Debt?

Apr 16
Health Check: How Prudently Does Transgene (EPA:TNG) Use Debt?

What Type Of Shareholders Own The Most Number of Transgene SA (EPA:TNG) Shares?

Mar 12
What Type Of Shareholders Own The Most Number of Transgene SA (EPA:TNG) Shares?

Does Transgene's (EPA:TNG) Share Price Gain of 62% Match Its Business Performance?

Jan 23
Does Transgene's (EPA:TNG) Share Price Gain of 62% Match Its Business Performance?

Shareholder Returns

TNGFR BiotechsFR Market
7D-9.1%1.0%1.2%
1Y19.2%303.3%1.2%

Return vs Industry: TNG underperformed the French Biotechs industry which returned 292.1% over the past year.

Return vs Market: TNG exceeded the French Market which returned 0.1% over the past year.

Price Volatility

Is TNG's price volatile compared to industry and market?
TNG volatility
TNG Average Weekly Movement8.5%
Biotechs Industry Average Movement9.3%
Market Average Movement4.4%
10% most volatile stocks in FR Market11.2%
10% least volatile stocks in FR Market2.4%

Stable Share Price: TNG's share price has been volatile over the past 3 months compared to the French market.

Volatility Over Time: TNG's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of French stocks.

About the Company

FoundedEmployeesCEOWebsite
1979147Alessandro Rivawww.transgene.fr

Transgene SA, a biotechnology company, designs and develops therapeutic vaccines and oncolytic viruses for the treatment of cancer in France. It involved in developing TG4050, a therapeutic vaccine that is in Phase II clinical trial for the treatment of ovarian cancer, and head and neck cancers; TG4001, a therapeutic vaccine, which is in Phase II clinical trial for the treatment of human papillomavirus (HPV 16) positive cancers; TG6002, an oncolytic virus that is in Phase I/IIa clinical trial for the treatment of solid tumors, including gastrointestinal adenocarcinoma; and BT-001, an oncolytic virus, which is in Phase I/II clinical trial for the treatment of solid tumors. The company also develops TG6050 for the treatment of non-small cell lung cancer that is in Phase 1 clinical trial; and Pexa-Vec, an oncolytic virus for the treatment of solid tumors.

Transgene SA Fundamentals Summary

How do Transgene's earnings and revenue compare to its market cap?
TNG fundamental statistics
Market cap€225.63m
Earnings (TTM)-€36.78m
Revenue (TTM)€7.58m
29.8x
P/S Ratio
-6.1x
P/E Ratio

Is TNG overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
TNG income statement (TTM)
Revenue€7.58m
Cost of Revenue€36.77m
Gross Profit-€29.19m
Other Expenses€7.59m
Earnings-€36.78m

Last Reported Earnings

Jun 30, 2025

Next Earnings Date

Mar 24, 2026

Earnings per share (EPS)-0.13
Gross Margin-385.35%
Net Profit Margin-485.56%
Debt/Equity Ratio-862.0%

How did TNG perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/02/06 14:39
End of Day Share Price 2026/02/06 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Transgene SA is covered by 5 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Arsene GuekamCIC Market Solutions (ESN)
Michael Thomas CooperEdison Investment Research
Martial DescouturesODDO BHF Corporate & Markets